Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 11, 2010, Pages 1867-1871

  Katsuda, Hiromu ^a   Yamashita, Mariko ^a   Katsura, Hideyuki ^a   Yu, Jia ^a   Waki, Yoshihiro ^b   Nagata, Naoto ^a   Sai, Yoshimichi ^a   Miyamoto, Ken Ichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cimetidine; Cisplatin; Inhibition; Nephrotoxicity; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; CIMETIDINE; CISPLATIN; CREATININE; NITROGEN; ORGANIC CATION TRANSPORTER 2; REACTIVE OXYGEN METABOLITE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CELL STRAIN; CELL STRAIN HEK293; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG UPTAKE; EMBRYO; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; KIDNEY MASS; LIVER WEIGHT; MALE; NEPHROTOXICITY; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION;

ACETYLCYSTEINE; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CIMETIDINE; CISPLATIN; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; ORGANIC CATION TRANSPORT PROTEINS; OSTEOSARCOMA; PLATINUM; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RENAL AGENTS;

EID: 78249280269     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.1867     Document Type: Article

References (18)

1. Tomita K., Tsuchiya H., Clin. Ther., 11, 43-52 (1989).
2. Yonezawa A., Masuda S., Nishihara K., Yano I., Katsura T., Inui K., Biochem. Pharmacol., 70, 1823-1831 (2005).
3. Ciarimboli G., Ludwig T., Lang D., Pavenstädt H., Koepsell H., Piechota H. J., Haier J., Jaehde U., Zisowsky J., Schlatter E., Am. J. Pathol., 167, 1477-1484 (2005).
4. Sugihara K., Nakano S., Gemba M., Jpn. J. Pharmacol., 44, 71-76 (1987).
5. De Martinis B. S., Bianchi M. D., Pharmacol. Res., 44, 317-320 (2001).
6. Schaaf G. J., Maas R. F., de Groene E. M., Fink-Gremmels J., Free Radical Res., 36, 835-843 (2002).
7. Sleifer D. T., Offerman J. J., Mulder N. H. Verweij M., van der Hem G. K., Schraffordt Koops H. S., Meijer S., Cancer, 60, 2823-2828 (1987).
8. Baliga R., Zhang Z., Baliga M., Ueda N., Shah S. V., Kidney Int., 54, 1562-1569 (1998).
9. Shu Y., Bello C. L., Mangravite L. M., Feng B., Giacomini K. M., J. Pharmacol. Exp. Ther., 299, 392-398 (2001).
10. Waki Y., Miyamoto K., Kasugai S., Ohya K., Jpn. J. Cancer Res., 86, 430-476 (1995).
11. Kawahara M., Takahashi Y., Takazawa K., Tsuchiya H., Tomita K., Yokogawa K., Miyamoto K., Anticancer Res., 28, 1681-1686 (2008).
12. Adedoyin A., Aarons L., Houston J. B., Xenobiotica, 17, 595-604 (1987).
13. Yokoo S., Yonezawa A., Masuda S., Fukatsu A., Katsura T., Inui K., Biochem. Pharmacol., 74, 477-487 (2007).
14. Ji L., Matsuda S., Saito H., Inui K., Kidney Int., 62, 514-524 (2002).
15. Reece P. A., Stafford I., Russell J., Gill P. G., Cancer Chemother. Pharmacol., 15, 295-299 (1985).
16. Naziroglu M., Karaoglu A., Aksoy A. O., Toxicology, 195, 221-230 (2004).
17. Liu H., Baliga R., Kidney Int., 63, 1687-1696 (2003).
18. Lu Y., Cederbaun A. I., Toxicol. Sci., 89, 515-523 (2006).